Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
$8.22
$8.17
$4.02
$9.15
$376.37M2.82692,487 shsN/A
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
$8.37
$8.37
$2.66
$8.55
$401.26M0.522.97 million shsN/A
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
$39.95
$38.88
$9.39
$39.99
$5.50B1.063.62 million shsN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$2.80
-2.8%
$4.44
$0.80
$9.62
$339.64M1.52.19 million shs425,623 shs
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$19.22
-1.5%
$18.97
$10.06
$21.72
$361.72M0.8249,977 shs2,138 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
0.00%0.00%0.00%0.00%+29.20%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-10.28%-18.18%-32.55%-9.15%-29.41%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
-1.26%+3.77%-3.70%+9.85%+80.74%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
N/AN/AN/AN/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
4.1555 of 5 stars
4.41.00.04.12.82.50.0
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
2.4855 of 5 stars
2.55.00.80.01.81.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
N/AN/AN/AN/A
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/A
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
2.00
HoldN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
2.71
Moderate Buy$6.29124.49% Upside
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
3.00
Buy$24.0024.87% Upside

Current Analyst Ratings

Latest ADMS, CNCE, NATR, MRSN, and ISEE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/19/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Neutral$5.00
3/13/2024
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.50 ➝ $24.00
2/29/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$9.00
2/29/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$1.00 ➝ $5.00
2/29/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$6.00
2/29/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$7.00
2/29/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$2.00 ➝ $7.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
$74.46M5.05N/AN/A($0.47) per share-17.49
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
$32.58M12.32N/AN/A$3.24 per share2.58
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
N/AN/AN/AN/A$4.43 per shareN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$36.85M9.22N/AN/A$0.31 per share9.03
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$445.32M0.81$1.55 per share12.39$8.36 per share2.30

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/A
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/A
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
-$185.21M-$1.76N/AN/AN/AN/A-57.00%-46.15%N/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$171.67M-$1.50N/AN/AN/A-465.80%-282.36%-62.64%5/14/2024 (Estimated)
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$15.08M$0.7724.96N/A3.39%12.25%7.75%5/7/2024 (Confirmed)

Latest ADMS, CNCE, NATR, MRSN, and ISEE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/AN/A  
3/12/2024Q4 2023
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A$0.45+$0.45$0.44N/A$108.94 million
2/28/202412/31/2023
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$0.16-$0.16N/A-$0.16$22.59 million$10.70 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
N/AN/AN/AN/AN/A
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/AN/A
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
N/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
21.25
4.53
4.17
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/A
9.03
9.03
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
0.20
15.53
15.53
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
0.63
3.36
3.36
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A
2.16
1.29

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
13845.79 million37.13 millionOptionable
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
6447.94 million42.51 millionOptionable
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
163137.78 million134.06 millionOptionable
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
123121.30 million106.14 millionOptionable
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
81418.82 million17.94 millionOptionable

ADMS, CNCE, NATR, MRSN, and ISEE Headlines

SourceHeadline
Natures Sunshines Impact Report Highlights Achievements and Continued Commitment Toward SustainabilityNature's Sunshine's Impact Report Highlights Achievements and Continued Commitment Toward Sustainability
prnewswire.com - April 24 at 10:15 AM
Nature’s Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ETNature’s Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ET
finance.yahoo.com - April 23 at 7:40 PM
Natures Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ETNature's Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ET
globenewswire.com - April 23 at 4:05 PM
Those who invested in Natures Sunshine Products (NASDAQ:NATR) five years ago are up 126%Those who invested in Nature's Sunshine Products (NASDAQ:NATR) five years ago are up 126%
finance.yahoo.com - April 21 at 1:52 PM
Natures Sunshine Products, Inc.s (NASDAQ:NATR) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?Nature's Sunshine Products, Inc.'s (NASDAQ:NATR) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
finance.yahoo.com - April 4 at 2:56 PM
Natures Sunshine Products, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsNature's Sunshine Products, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
finance.yahoo.com - March 15 at 7:55 AM
Natures Sunshine Shares Touch 52-Week High After 4Q UpdateNature's Sunshine Shares Touch 52-Week High After 4Q Update
marketwatch.com - March 14 at 8:49 AM
Why Natures Sunshine (NATR) Stock Is Up TodayWhy Nature's Sunshine (NATR) Stock Is Up Today
finance.yahoo.com - March 13 at 1:46 PM
Natures Sunshine Products, Inc.: Natures Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsNature's Sunshine Products, Inc.: Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial Results
finanznachrichten.de - March 13 at 7:45 AM
Natures Sunshine: Q4 Earnings SnapshotNature's Sunshine: Q4 Earnings Snapshot
timesunion.com - March 12 at 8:59 PM
Natures Sunshine (NASDAQ:NATR) Misses Q4 Sales TargetsNature's Sunshine (NASDAQ:NATR) Misses Q4 Sales Targets
finance.yahoo.com - March 12 at 8:59 PM
Natures Sunshine Products Inc (NATR) Reports Significant Growth in Q4 and Full Year 2023 EarningsNature's Sunshine Products Inc (NATR) Reports Significant Growth in Q4 and Full Year 2023 Earnings
gurufocus.com - March 12 at 6:04 PM
Natures Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsNature's Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial Results
globenewswire.com - March 12 at 4:05 PM
Preview: Natures Sunshine Productss EarningsPreview: Natures Sunshine Products's Earnings
benzinga.com - March 11 at 3:30 PM
Natures Sunshine (NATR) Q4 Earnings: What To ExpectNature's Sunshine (NATR) Q4 Earnings: What To Expect
finance.yahoo.com - March 11 at 10:30 AM
Nature’s Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ETNature’s Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ET
finance.yahoo.com - February 20 at 7:35 PM
Natures Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ETNature's Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ET
globenewswire.com - February 20 at 4:05 PM
Is There Now An Opportunity In Natures Sunshine Products, Inc. (NASDAQ:NATR)?Is There Now An Opportunity In Nature's Sunshine Products, Inc. (NASDAQ:NATR)?
finance.yahoo.com - February 6 at 10:21 AM
Natures Sunshine Products: Unconvincing Trajectory Despite ImprovementsNature's Sunshine Products: Unconvincing Trajectory Despite Improvements
seekingalpha.com - January 31 at 4:43 AM
Nature’s Sunshine Announces Participation at the 26th Annual Needham Growth Conference on January 19, 2024Nature’s Sunshine Announces Participation at the 26th Annual Needham Growth Conference on January 19, 2024
finance.yahoo.com - January 2 at 8:03 PM
Natures Sunshine Products, Inc. (NASDAQ:NATR) is definitely on the radar of institutional investors who own 39% of the companyNature's Sunshine Products, Inc. (NASDAQ:NATR) is definitely on the radar of institutional investors who own 39% of the company
finance.yahoo.com - December 21 at 3:09 PM
Nature’s Sunshine Recognized with Best Company Culture AwardNature’s Sunshine Recognized with Best Company Culture Award
finance.yahoo.com - December 19 at 10:07 AM
Natures Sunshine Products Stock (NASDAQ:NATR), Quotes and News SummaryNatures Sunshine Products Stock (NASDAQ:NATR), Quotes and News Summary
benzinga.com - December 12 at 11:35 PM
Nature`s Sunshine Products (NATR) Price Target Increased by 10.26% to 21.93Nature`s Sunshine Products (NATR) Price Target Increased by 10.26% to 21.93
msn.com - November 27 at 7:16 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adamas Pharmaceuticals logo

Adamas Pharmaceuticals

NASDAQ:ADMS
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
Concert Pharmaceuticals logo

Concert Pharmaceuticals

NASDAQ:CNCE
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.
IVERIC bio logo

IVERIC bio

NASDAQ:ISEE
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.
Mersana Therapeutics logo

Mersana Therapeutics

NASDAQ:MRSN
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Nature

Nature's Sunshine Products

NASDAQ:NATR
Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.